Worldwide Organ Preservation Solutions Market Overview 2013 - 2019
M2 - Thu May 01, 3:27AM CDT
Research and Markets (http://www.researchandmarkets.com/research/z5ms2f/organ) has announced the addition of the "Organ Preservation Solutions Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019" report to their offering. Some of the prominent players in the organ preservation solutions market that have been profiled in this report include Dr. Franz K?hler Chemie GmbH, Teva Pharmaceutical Industries Ltd., Bristol-Myers Squibb, BioLife Solutions, Inc., XVIVO Perfusion AB and ToleroTech, Inc. This report studies the global organ preservation solutions market based on the various solutions available in the market in which organs are preserved, type of preservation techniques used and the major geographic markets. The global market for organ preservation solutions has been segmented into nine major solutions that include Viaspan, Custodiol HTK, Renograf, Hypothermosol, Perfadex, Lifor, HBS Solution, siRNA Transplant Solution and others (Ross-Marshall Citrate Solutions, Celsior Solution, Phosphate-Buffered Sucrose Solution, ET-Kyoto, TranSend, HetaFreeze, MaPersol and CryoStor). On the basis of preservation techniques, the market has been segmented into three categories namely hypothermic perfusion preservation (HPP), static cold storage (SCS) and others (that include normothermic preservation and oxygen insufflation techniques). Geographically, the report studies the global market with respect to four main regions, namely, North America, Europe, Asia-Pacific and Rest of the World (RoW). The market size and forecasts in terms of revenue (USD million) for the period 2011 to 2019, considering 2012 as the base year, have been provided for each solution type, technique type and geographic region. The report also provides the compounded annual growth rate (% CAGR) for the forecast period 2013 to 2019 for all the aforementioned segments. The market overview section of the report discusses the market dynamics that include drivers, restraints and opportunities influencing the market. This section also covers a market attractiveness analysis (by geography) for the year 2012 and Porter's five forces analysis for the global organ preservation solutions market. Market share (%) for the major players operating in this market has also been provided for the year 2012 in the competitive landscape section, followed by a list of recommendations for the existing and new players. The report also includes company profiles of key players operating in various segments of the market. Each company profile includes the business overview, financial overview, product portfolio, business strategies and recent developments of the respective company. Key Topics Covered: Chapter 1 Introduction Chapter 2 Executive Summary Chapter 3 Market Overview - Aging global population - Global rate of aging population - Technological advancements - Increasing reimbursement scenario - Increase in per capita healthcare expenditure - Lack of organ donors - Widening Gap Between Patients Receiving Organ Transplants and Number of Donors in the U.S. (1998 - 2010) - High cost of procedure - Collaboration with research-oriented organizations and medical institutes to ensure retention of customer base - Porter's Five Force Analysis for the Global Organ Preservation Solutions Market Chapter 4 Global Organ Preservation Solutions Market, By Solution, 2011 - 2019 (USD Million) - Viaspan - Custodiol HTK - (Histidine-Tryptophan-Ketoglutarate) Solution - Renograf - Hypothermosol - Perfadex - Lifor - Human bioSystem (HBS) Solution - siRNA Transplant Solution - Others Chapter 5 Global Organ Preservation Solutions Market, By Preservation Technique, 2011 - 2019 (USD Million) - Hypothermic Perfusion Preservation (HPP) - Static Cold Storage (SCS) Chapter 6 Global Organ Preservation Solutions Market, By Geography, 2011 - 2019 (USD Million) Chapter 7 Competitive Landscape Chapter 8 Recommendations - Long term contracts with healthcare service providers - Broadening of distribution network - Product innovation Chapter 9 Company Profiles - 21st Century Medicine - BioLife Solutions, Inc. - BioTime, Inc. - Bristol-Myers Squibb - Claris Lifesciences Limited - CryoLife, Inc. - Dr. Franz K?hler Chemie GmbH - Lifeline Scientific - Teva Pharmaceutical Industries Ltd. - ToleroTech, Inc. - XVIVO Perfusion AB For more information visit http://www.researchandmarkets.com/research/z5ms2f/organ
YieldBoost CRY To 11.8% Using Options
StockOptionsChannel.com - Wed Apr 30, 10:37AM CDT
Shareholders of CryoLife, Inc. looking to boost their income beyond the stock's 1.2% annualized dividend yield can sell the October covered call at the $10 strike and collect the premium based on the 45 cents bid, which annualizes to an additional...
CryoLife Posts Record First Quarter Revenues of $35.7 Million
PR Newswire - Tue Apr 29, 7:14AM CDT
First Quarter Highlights:
CryoLife Receives FDA 510(k) Clearance for PerClot® Topical Hemostatic Powder in the U.S.
PR Newswire - Tue Apr 29, 7:04AM CDT
CryoLife, Inc. (NYSE: CRY), a leading medical device and tissue processing company focused on cardiac and vascular surgery, announced today that it has received 510(k) clearance for PerClot Topical hemostatic powder from the U.S. Food and Drug Administration (FDA). This clearance allows CryoLife to begin commercialization of PerClot Topical hemostatic powder in the U.S. The Company plans to begin shipping PerClot Topical hemostatic powder in June of this year.
CryoLife Announces Release Date and Teleconference Call Details for 2014 First Quarter Financial Results
PR Newswire - Tue Apr 15, 7:34AM CDT
CryoLife, Inc. (NYSE: CRY), a leading medical device and tissue processing company focused on cardiac and vascular surgery, announced today that 2014 first quarter financial results will be released on Tuesday, April 29, 2014. On that day, the Company will hold a teleconference call and live webcast at 10:00 a.m. Eastern Time to discuss the results, followed by a question and answer session hosted by Steven G. Anderson, president and chief executive officer of CryoLife, Inc.
CryoLife Receives FDA Approval to Begin Clinical Trials for PerClot® in the U.S.
PR Newswire - Wed Apr 02, 7:32AM CDT
CryoLife, Inc. (NYSE: CRY), a leading medical device and tissue processing company focused on cardiac and vascular surgery, announced today that it has received approval of its Investigational Device Exemption (IDE) for PerClot from the United States Food and Drug Administration (FDA). This approval allows CryoLife to begin its pivotal clinical trial to gain approval to commercialize PerClot in the U.S. The Company plans to begin enrollment in the trial in the second quarter of 2014, and could potentially receive pre-market approval from the FDA by the end of 2015.
CryoLife Acquires Distribution Rights and Purchase Option for ProCol® Vascular Bioprosthesis for Hemodialysis Access
PR Newswire - Thu Mar 27, 7:34AM CDT
CryoLife, Inc. (NYSE: CRY), a leading medical device and tissue processing company focused on cardiac and vascular surgery, announced today that it has acquired the exclusive worldwide distribution rights for the ProCol Vascular Bioprosthesis ("ProCol"
CryoLife Continues To Support Customer Education With Third Central Venous Pathology Summit
PR Newswire - Wed Mar 19, 7:34AM CDT
CryoLife, Inc. (NYSE: CRY), a leading medical device and tissue processing company focused on cardiac and vascular surgery, announced today that it will host its third Central Venous Pathology (CVP) Summit on March 25-27, 2014 at CryoLife's training facility at its corporate headquarters in suburban Atlanta. The Company expects that over 80 physicians and dialysis therapy professionals will attend the CVP Summit.
Concise Analysis of the United States Regenerative Medicine Market - Forecasts to 2016
M2 - Wed Mar 12, 6:14AM CDT
Research and Markets (http://www.researchandmarkets.com/research/4lq46f/regenerative) has announced the addition of the "Concise Analysis of the United States Regenerative Medicine Market - Forecasts to 2016" report to their offering. There is a high demand for synthetic organ transplants in the market. Regenerative medicine helps in the development of artificial organs. The introduction of artificial organs for implantation is expected to encourage many vendors and research organizations to develop advanced stem cell products, therapies, and regenerative products. It will also help reduce the long organ waiting list. For instance, custom-made windpipe can be made using regenerative products within a week. The first ever implant of a synthetic trachea took place in June 2011. The synthetic trachea was made from minuscule plastic fibers and was covered in stem cells taken from a human bone marrow. Surgeons successfully implanted this synthetic trachea into a 36-year-old patient with late-stage tracheal cancer at Karolinska University Hospital in Stockholm. Thus, the use of synthetic organs in transplant surgeries is expected to have a positive impact on the growth of the market. According to the report, one of the main drivers of this market is the increasing prevalence of degenerative diseases. Regenerative products have helped in addressing the unmet needs of various disease areas. Another major driver of the market is the significant advances seen in R&D. Key Topics Covered: 1. Executive Summary 2. List of Abbreviations 3. Introduction 4. Market Research Methodology 5. Scope of the Report 6. Market Landscape 7. Vendor Landscape 8. Buying Criteria 9. Market Growth Drivers 10. Drivers and their Impact 11. Market Challenges 12. Impact of Drivers and Challenges 13. Market Trends 14. Key Vendor Analysis 15. Other Reports in this Series Companies Mentioned: - Advanced Cell Technology Inc. - Arteriocyte Inc. - Athersys Inc. - Baxter International Inc. - CryoLife - Cytori Therapeutics Inc. - Genzyme Corp. - Geron Corp. - InVivo Therapeutics - Inc. - Integra Life Sciences Holdings Corp. - Kensey Nash Corp. - Kinetic Concepts Inc. - Medtronic Inc. - NeoStem Inc. - Osiris Therapeutics Inc. - Osteotech Inc. - RTI Biologics Inc. - Stryker Corp. - Zimmer Holdings Inc. For more information visit http://www.researchandmarkets.com/research/4l...generative
Organ Preservation Solutions Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019
M2 - Mon Feb 24, 5:18AM CST
Research and Markets (http://www.researchandmarkets.com/research/5mpr3g/organ) has announced the addition of the "Organ Preservation Solutions Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019" report to their offering. The rise in incidences of organ failure in kidney, liver and heart patients across the globe is augmenting the demand for organ transplant procedures.This has further led to a rise in the demand for organ preservation solutions that help maintain the organs' viability from the time of donation to transplantation. Market growth for organ preservation solutions will also be propelled by the rise in the number of elderly people worldwide since, risk of organ failure in people of this age group is higher. Also, the American Society of Nephrology states that an aged patient's body shows less graft rejection and that has led to increased preference for organ transplants by surgeons for them. According to the U.S. Department of Health and Human Services, in 2011, 60% of the total number of individuals who underwent organ transplantation procedures in the U.S. were beyond 50 years of age. The global market for organ preservation solutions is expected to grow at a CAGR of 16.5% from 2013 to 2019 to reach an estimated value of USD 0.20 billion in 2019. The growth of this market will also be driven by the launch of technologically advanced products such as Lifor. Lifor is manufactured by Lifeblood Medical, Inc. and is currently utilized for research purposes only. It is also termed as a blood surrogate and once its effectiveness is clinically proven for preserving human and veterinary organs, the market for the same will grow significantly. Both the developed and developing countries have recorded growth in per capita healthcare expenditure which would provide people with less expensive and better healthcare services. This will also enable the patients to afford organ transplant procedures and hence the organ preservation solutions market will grow. However, growth of this market may get hampered due to high cost of transplantation procedures and lack of organ donors which may shift the preferences of surgeons towards artificial organs. Key Topics Covered - Introduction - Executive Summary - Market Overview - Global Organ Preservation Solutions Market, By Solution, 2011 - 2019 (USD Million) - Global Organ Preservation Solutions Market, By Preservation Technique, 2011 - 2019 (USD Million) - Global Organ Preservation Solutions Market, By Geography, 2011 - 2019 (USD Million) - Competitive Landscape - Recommendations - Company Profiles Companies Mentioned - 21st Century Medicine - BioLife Solutions - BioTime - Bristol-Myers Squibb - Claris Lifesciences - CryoLife - Dr. Franz K?hler Chemie - Lifeline Scientific - Teva Pharmaceutical Industries - ToleroTech - XVIVO Perfusion For more information visit http://www.researchandmarkets.com/research/5mpr3g/organ About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products.
NYSE stocks posting largest percentage decreases
AP - Thu Feb 20, 5:05PM CST
NEW YORK (AP) — A look at the 10 biggest percentage decliners on New York Stock Exchange at the close of trading:
Why CryoLife, Inc. Shares Have Gone Ice-Cold
Sean Williams, The Motley Fool - Motley Fool - Thu Feb 20, 12:26PM CST
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of CryoLife , a global human tissue...
CryoLife Fourth Quarter 2013 Revenues Increased 8 Percent to a Record $35.5 Million
PR Newswire - Thu Feb 20, 7:04AM CST
CryoLife, Inc. (NYSE: CRY), a leading medical device and tissue processing company focused on cardiac and vascular surgery, announced today its results for the fourth quarter and full year of 2013. Revenues for the fourth quarter of 2013 increased 8 percent to a fourth quarter record of $35.5 million compared to $32.8 million for the fourth quarter of 2012. Revenues for the full year of 2013 increased 7 percent to a record $140.8 million compared to $131.7 million for the full year of 2012.
CryoLife's board approves USD0.0275 per share dividend for Q1 2014
M2 - Thu Feb 20, 4:14AM CST
The board of directors of CryoLife Inc (NYSE:CRY), a medical company, on Wednesday declared a dividend of USD0.0275 per share of its common stock outstanding for Q1 2014.
CryoLife, Inc.Corporate Event Announcement Notice
Wall Street Horizon - Wed Feb 19, 7:52PM CST
Pacific Coal Resources Ltd. (TSXV: PAK) announces the voluntary delisting of 74,749,976 warrants, being all of the Company's warrants currently trading on the TSX Venture Exchange under the symbol PAK.WT. Due to the minimal trading volume of the warrants, the Company is electing to delist the warrants to further its ongoing cost reduction initiative undertaken in 2012. The warrants are expected to be delisted at market close on March 18, 2013, being 20 trading days following the date of this release, as required by the TSXV.
CryoLife Announces Quarterly Cash Dividend for the First Quarter 2014
PR Newswire - Wed Feb 19, 4:05PM CST
CryoLife, Inc. (NYSE: CRY), a leading medical device and tissue processing company focused on cardiac and vascular surgery, announced today that its Board of Directors has approved a quarterly cash dividend for the first quarter 2014 of $0.0275 per share of common stock outstanding. The quarterly cash dividend of $0.0275 per share will be paid on March 21, 2014 to all common stockholders of record as of March 14, 2014. The ex-dividend date for the quarterly dividend is March 12, 2014.
CryoLife to Present at 2014 RBC Capital Markets' Global Healthcare Conference
PR Newswire - Tue Feb 18, 3:52PM CST
CryoLife, Inc. (NYSE: CRY), a leading medical device and tissue processing company focused on cardiac and vascular surgery, announced today that it will participate in the upcoming 2014 RBC Capital Markets' Global Healthcare Conference on Wednesday, February 26, 2014 at The New York Palace Hotel in New York City.
CryoLife Announces Expansion in Asia Pacific Markets
PR Newswire - Tue Feb 18, 7:34AM CST
CryoLife, Inc. (NYSE: CRY), a leading medical device and tissue processing company focused on cardiac and vascular surgery, announced today the establishment of CryoLife Asia Pacific Pte. Ltd., a wholly-owned subsidiary of CryoLife, Inc., to expand the Company's presence in the rapidly growing Asia Pacific medical device market. To support the new subsidiary, CryoLife will relocate Mr. Rich Gridley, vice president sales, Canada, Asia-Pacific, and The Americas, to a new regional headquarters in Singapore.
Implant Sciences Announces Order Valued at up to $1,500,000 in Latin America
PR Newswire - Thu Feb 13, 6:00AM CST
Implant Sciences Corporation (OTCQB:IMSC), a high technology supplier of systems and sensors for homeland security and defense markets, today announced it has won an order for its QS-H150 handheld explosives trace detectors (ETD), associated consumables, and services. The total value of the order including consumables and service is expected to be approximately $1,500,000, with the first $1,000,000 to be delivered to the customer during Implant Sciences' fiscal year 2014 for deployment in Latin America.